Valbiotis SAS

Research Valbiotis SAS (ALVAL) on Bullrun: market cap EUR 17.62M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerALVAL
• ExchangePA
• CountryFrance
• SectorConsumer Defensive
• IndustryPackaged Foods
• CurrencyEUR
• Market capEUR 17.62M
• Financial periodFY2025
• RevenueEUR 905.00K
• Revenue growth417.1%
• Net income-EUR 9.42M
• Free cash flow-EUR 8.19M
• Gross margin-146.2%

Valuation Snapshot

latest market cap is EUR 17.62M.

About Valbiotis SAS

Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia. The company offers supplements for immunity and vitality, health and wellbeing, metabolic and cardiovascular health, and beauty and physical comfort. It also develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure;

Frequently asked questions

What is Valbiotis SAS's market cap?

Valbiotis SAS's market capitalization is EUR 17.62M.

What does Valbiotis SAS do?

Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia. The company offers supplements for immunity and vitality, health and wellbeing, metabolic and cardiovascular health, and beauty and physical comfort.